Article

CPT code, reimbursement set for tear osmolarity test

The American Medical Association (AMA) has published a new Current Procedural Terminology (CPT) code that applies to a proprietary osmolarity test (TearLab).

San Diego-The American Medical Association (AMA) has published a new Current Procedural Terminology (CPT) code that applies to a proprietary osmolarity test (TearLab), according to the company.

The code is 83861; microfluidic analysis utilizing an integrated collection and analysis device, tear osmolarity (for microfluidic tear osmolarity of both eyes, report 83861 twice). This code falls under the chemistry subsection of the pathology and laboratory section of the CPT Codebook and will be listed under the clinical laboratory fee schedule by the Centers for Medicare and Medicaid Services (CMS). Patient co-payments and deductibles do not apply to services paid under the Medicare clinical laboratory fee schedule.

“We are very pleased that the AMA has created this CPT code that describes the . . . test,” said Elias Vamvakas, TearLab’s chief executive officer. “The establishment of this code demonstrates the uniqueness, utility, and value of our patented lab-on-a-chip technology.”

CMS has published its recommended payment determination for new test codes, and it includes a proposed reimbursement rate, effective in January, for the osmolarity test.

CMS will reimburse the new code at $24.01 per eye. Reimbursement will be available only for offices that have a moderate complex Clinical Laboratory Improvement Amendments (CLIA) certificate until the marketer of the test receives a CLIA waiver categorization from the FDA. The FDA is reviewing the waiver application.

“With FDA approval last year, reimbursement marks the achievement of the second of our three key milestones for U.S. commercialization,” Vamvakas said. “We look forward to receiving our CLIA waiver certificate, which will make it much simpler for individual doctors to provide the test for their patients.”

The osmolarity system uses a novel lab-on-a-chip approach that requires less than 50 nl of tear fluid to measure tear osmolarity. The system aims to eliminate the challenges that previously prevented point-of-care osmolarity testing. It can produce a sample-to-answer result in less than 30 seconds, according to the company.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.